SLC5A2 and type 2 diabetes mellitus: There are numerous placebo-controlled studies that have investigated the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) in people with type 2 diabetes (EMPAREG, CANVAS, CREDENCE, DECLARE) [1].